Profile data is unavailable for this security.
About the company
Sinphar Pharmaceutical Co., Ltd. is principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company is also engaged in the sales of functional food products. The Company’s principal products include ointment, gel, cream, hard and soft capsules, sugar-coated tablets, film-coated tablets, suppositories, powders and granules, lozenges, soft candies, oral and topical liquid medicines, injections, dry medicated powers, functional food products, medical equipment and cosmetics. The Company mainly sells its products to hospitals, drug stores, clinics, dealers and distributors. Its primary markets are located in Taiwan and overseas countries.
- Revenue in TWD (TTM)2.97bn
- Net income in TWD405.43m
- Incorporated1977
- Employees984.00
- LocationSinphar Pharmaceutical Co LtdNo.84Chung Shan Road, Chung Shan VillageDONGSHAN 269TaiwanTWN
- Phone+886 39581101
- Fax+886 39580187
- Websitehttp://www.sinphar.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unicocell Biomed Co Ltd | -100.00bn | -100.00bn | 4.72bn | -- | -- | 8.35 | -- | -- | -- | -- | -- | 10.15 | -- | -- | -- | -- | -- | -24.25 | -- | -25.60 | -- | 69.89 | -- | -705.40 | 25.16 | -- | 0.1141 | -- | 70.79 | 34.96 | 7.73 | -- | 9.00 | -- |
| Nang Kuang Pharmaceutical Co Ltd | 2.11bn | 159.13m | 5.45bn | 552.00 | 34.31 | 2.45 | 15.97 | 2.59 | 1.57 | 1.57 | 20.83 | 22.08 | 0.5823 | 1.83 | 7.93 | -- | 4.40 | 6.75 | 6.29 | 9.64 | 34.36 | 34.77 | 7.56 | 12.22 | 0.6212 | 23.03 | 0.117 | 82.74 | 10.81 | 6.92 | -43.63 | 14.41 | 19.51 | 10.76 |
| Sinphar Pharmaceutical Co Ltd | 2.97bn | 405.43m | 6.25bn | 984.00 | 15.43 | 1.94 | 10.05 | 2.10 | 2.41 | 2.41 | 17.68 | 19.22 | 0.4824 | 2.25 | 5.70 | -- | 6.35 | -0.0147 | 8.35 | -0.0203 | 37.81 | 37.49 | 13.17 | -0.0344 | 1.52 | 33.73 | 0.3542 | 79.70 | 3.72 | 5.98 | 67.01 | 111.88 | 3.31 | 58.49 |
| China Chemical & Pharmaceutical Co Ltd | 8.76bn | 327.98m | 6.62bn | 1.40k | 20.19 | 0.8849 | 10.06 | 0.7552 | 1.10 | 1.10 | 29.36 | 25.09 | 0.6814 | 2.21 | 5.55 | -- | 2.57 | 3.69 | 3.55 | 4.96 | 36.61 | 36.56 | 3.77 | 5.50 | 0.8324 | -- | 0.3172 | 52.77 | 1.40 | 2.50 | -32.51 | -2.72 | 3.57 | -8.97 |
| Tanvex Biopharma Inc | 34.63m | -1.95bn | 6.66bn | -- | -- | 13.41 | -- | 192.30 | -14.52 | -14.52 | 0.2583 | 3.03 | 0.0121 | 0.1173 | 8.23 | -- | -68.18 | -49.24 | -83.48 | -53.18 | 57.27 | 49.20 | -5,622.48 | -10,835.34 | 0.594 | -133.04 | 0.84 | -- | 174.11 | -- | -30.22 | -- | -8.09 | -- |
| Pell Bio Med Technology Co Ltd | 17.97m | -424.82m | 7.54bn | -- | -- | 5.30 | -- | 419.65 | -8.89 | -8.89 | 0.3657 | 24.88 | 0.0137 | 12.58 | 4.28 | -- | -32.49 | -- | -34.55 | -- | -152.30 | -- | -2,379.23 | -- | 17.33 | -- | 0.1043 | -- | 5.11 | -- | -73.27 | -- | -- | -- |
Data as of Jun 07 2024. Currency figures normalised to Sinphar Pharmaceutical Co Ltd's reporting currency: Taiwan Dollar TWD
2.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 09 May 2024 | 2.04m | 1.22% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 1.31m | 0.78% |
| Dimensional Fund Advisors Ltd.as of 30 Apr 2024 | 194.53k | 0.12% |
| DFA Australia Ltd.as of 31 Dec 2023 | 19.17k | 0.01% |
| American Century Investment Management, Inc.as of 09 May 2024 | 3.00k | 0.00% |
| LGT Capital Partners AG (Investment Management)as of 31 May 2023 | 1.00k | 0.00% |
More ▼
Data from 31 Mar 2024 - 06 Jun 2024Source: FactSet Research Systems Inc.
